Home Cart 0 Sign in  
X

[ CAS No. 100-09-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 100-09-4
Chemical Structure| 100-09-4
Chemical Structure| 100-09-4
Structure of 100-09-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 100-09-4 ]

Related Doc. of [ 100-09-4 ]

Alternatived Products of [ 100-09-4 ]

Product Details of [ 100-09-4 ]

CAS No. :100-09-4 MDL No. :MFCD00002542
Formula : C8H8O3 Boiling Point : -
Linear Structure Formula :- InChI Key :ZEYHEAKUIGZSGI-UHFFFAOYSA-N
M.W : 152.15 Pubchem ID :7478
Synonyms :
4-Methoxybenzoic acid;Draconic acid;NSC 32742
Chemical Name :4-Methoxybenzoic acid

Calculated chemistry of [ 100-09-4 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.12
Num. rotatable bonds : 2
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 39.89
TPSA : 46.53 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.84 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.56
Log Po/w (XLOGP3) : 1.96
Log Po/w (WLOGP) : 1.39
Log Po/w (MLOGP) : 1.32
Log Po/w (SILICOS-IT) : 1.21
Consensus Log Po/w : 1.49

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -2.29
Solubility : 0.781 mg/ml ; 0.00513 mol/l
Class : Soluble
Log S (Ali) : -2.56
Solubility : 0.417 mg/ml ; 0.00274 mol/l
Class : Soluble
Log S (SILICOS-IT) : -1.88
Solubility : 2.0 mg/ml ; 0.0132 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 100-09-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 100-09-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 100-09-4 ]
  • Downstream synthetic route of [ 100-09-4 ]

[ 100-09-4 ] Synthesis Path-Upstream   1~29

  • 1
  • [ 55326-10-8 ]
  • [ 253-82-7 ]
  • [ 100-09-4 ]
  • [ 99955-89-2 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1985, vol. 33, # 4, p. 1351 - 1359
  • 2
  • [ 735266-90-7 ]
  • [ 66572-55-2 ]
  • [ 100-09-4 ]
Reference: [1] Journal of Organic Chemistry, 2016, vol. 81, # 1, p. 238 - 249
  • 3
  • [ 100-09-4 ]
  • [ 829-35-6 ]
Reference: [1] Angewandte Chemie - International Edition, 2012, vol. 51, # 19, p. 4666 - 4670
[2] Chemical Communications (Cambridge, United Kingdom), 2012, vol. 48, # 92, p. 11307 - 11309,3
[3] European Journal of Medicinal Chemistry, 2013, vol. 65, p. 276 - 283
  • 4
  • [ 79-19-6 ]
  • [ 100-09-4 ]
  • [ 1014-25-1 ]
YieldReaction ConditionsOperation in experiment
86.4% at 80℃; for 2.5 h; General procedure: A stirring mixture of benzoic acid (0.2442 g, 2.0 mmol), thiosemicarbazide (0.1823 g, 2.0 mmol) and POCl3 (1.2 ml) was heated at 80 oC for 2.5 h. After cooling down to room temperature, water (2.5 mL) was added. The reaction mixture was refluxed for 4 h. After cooling, the mixture was basified to pH 8 by the dropwise addition of 40percent NaOH solution under stirring. The precipitate was filtered and recrystallized from ethanol to yield 0.3130 g of the target compound 1a as a white solid ,Yield: 88.3percent.
82%
Stage #1: at 75℃; for 0.5 h;
Stage #2: for 4 h; Reflux
General procedure: 5.1.1
5-(4-Morpholinophenyl)-1,3,4-thiadiazol-2-amine (59)
A mixture of 4-morpholinobenzoic acid (5.18 g, 25 mmol) and N-aminothiourea (2.28 g, 25 mmol) in POCl3 (7 ml) was stirred vigorously at 75 °C for 0.5 h.
After addition of H2O (30 ml), the reaction mixture was heated under reflux for 4 h and basified to pH 8 by 50percent NaOH solution.
The mixture was filtered and the filter cake was recrystallized from ethanol to yield 3.90 g of compound 59 as a yellow crystal. Yield: 59percent; The synthetic procedures of compounds 60–81 were the same as that described above. 5.1.1.2
5-(4-Methoxyphenyl)-1,3,4-thiadiazol-2-amine (61)
Yield: 82percent, mp: 219-220 °C (EtOH). ESI-MS m/z: 208.2 [M+H]+; 1H NMR (DMSO-d6) δ 3.80 (s, 3H), 7.01-7.03 (m, 2H), 7.23 (s, 2H), 7.67-7.69 (m, 2H).
81.3% at 75℃; for 0.5 h; General procedure: A stirring mixture of benzoic acid (7.32 g, 60 mmol), N-aminothiourea(6.38 g, 70 mmol) and POCl3 (20 ml) washeated at 75 °C for 0.5 h. After cooling down to room temperature,water was added. The reaction mixture was refluxedfor 4 h. After cooling, the mixture was basified to pH8 by the drop-wise addition of 50percent NaOH solution understirring. The precipitate was filtered and re-crystallized from ethanol
76.09% at 85℃; for 10 h; p-Anisic acid (3.04 g, 20 mmol) and thiosemicarbazide (1.82 g,20 mmol) were dissolved in 30 mL of phosphorus oxychloride, thereaction mixture was refluxed at 85 °C for 10 h. After the reactionfinished, the mixture was poured into ice water slowly and thensaturate NaOH solution was added to adjust the pH value to 8.0under vigorous stirring. The mixture was extracted with ethyl acetatethree times, the organic layer was washed with brine anddried over anhydrous sodium sulfate. After solvent evaporation, thecrude product was purified by recrystallization from anhydrousethanol to get 3.15 g white powder, yield: 76.09percent. Melting point:188.1-189.5 °C. FT-IR (KBr, Disc, cm1): 3409.28 (m, ν NH2), 3377.72(m,ν NH2), 3304.97 (w), 3105.35 (m), 1647.15 (m), 1608.48 (m, ν CN),1578.80 (w), 1511.49 (s, ν benzene), 1465.51(s), 1304.97 (w), 1267.34(w), 1246.65 (s, ν OCH3), 1174.54 (m, ν OCH3), 1128.97 (w), 1052.67 (w),1031.98 (m), 978.88 (w), 829.22 (m), 658.86 (w), 520.48 (w). 1HNMR (DMSO-d6, 400 MHz, ppm) δ: 7.69-7.67 (d, J= 8.0 Hz, 2H),7.28 (s, 2H, NH2), 7.03-7.01 (d, J =8.0 Hz, 2H), 3.80 (s, 3H, OCH3). 13CNMR (100 MHz, DMSO) δ 167.85, 160.24, 156.25, 127.77, 123.61,144.46, 55.27. MS (ESI) m/z: found, [M+H]+, 208.0542; molecularformula C9H9N3OS requires [M+H]+, 208.0544.
65%
Stage #1: for 5 h; Reflux
Stage #2: for 7 h; Cooling; Reflux
General procedure: A mixture ofappropriate 4-n-alkoxybenzoic acid (10 mmol) and (0.91 g, 10 mmol) of thiosemicarbazidewith 5 mL of phosphorus oxychloride was refluxed gently for 5 hr. After cooling 50 mL of water was added, the mixture was then refluxed for 7 hr and filtered, neutralizedwith potassium hydroxide. The precipitate was washed with water and recrystallized fromethanol-water to give titled compound [III]n.

Reference: [1] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 14, p. 6663 - 6668
[2] Tetrahedron, 2018, vol. 74, # 31, p. 4161 - 4167
[3] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 21, p. 5766 - 5775
[4] Medicinal Chemistry, 2014, vol. 10, # 4, p. 376 - 381
[5] Medicinal Chemistry Research, 2012, vol. 21, # 6, p. 816 - 824
[6] Bulletin of the Korean Chemical Society, 2010, vol. 31, # 8, p. 2345 - 2350
[7] Bulletin of the Korean Chemical Society, 2011, vol. 32, # 3, p. 1011 - 1016
[8] Dyes and Pigments, 2017, vol. 145, p. 152 - 159
[9] Asian Journal of Chemistry, 2010, vol. 22, # 7, p. 5289 - 5296
[10] Journal of Chemical Research, 2014, vol. 38, # 6, p. 347 - 350
[11] Molecular Crystals and Liquid Crystals, 2014, vol. 593, # 1, p. 34 - 42
[12] Bulletin of the Chemical Society of Japan, 1982, vol. 55, # 2, p. 637 - 638
[13] Heterocyclic Communications, 2007, vol. 13, # 6, p. 387 - 392
[14] European Journal of Medicinal Chemistry, 2009, vol. 44, # 7, p. 2782 - 2786
[15] Journal of Chemical Research, 2009, # 11, p. 674 - 676
[16] Journal of Chemical Research, 2009, # 11, p. 671 - 673
[17] Chinese Chemical Letters, 2010, vol. 21, # 3, p. 301 - 304
[18] Journal of Chemical Research, 2010, vol. 34, # 12, p. 719 - 721
[19] Synthetic Communications, 2011, vol. 41, # 6, p. 864 - 870
[20] Journal of Chemical Research, 2011, vol. 35, # 8, p. 442 - 443
[21] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 3, p. 1181 - 1187
[22] Oriental Journal of Chemistry, 2011, vol. 27, # 2, p. 373 - 383
[23] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 9, p. 2789 - 2795
[24] Asian Journal of Chemistry, 2012, vol. 24, # 6, p. 2739 - 2743
[25] Journal of Chemical Research, 2012, vol. 36, # 4, p. 218 - 221
[26] European Journal of Medicinal Chemistry, 2012, vol. 56, p. 56 - 69,14
[27] Indian Journal of Heterocyclic Chemistry, 2011, vol. 20, # 4, p. 403 - 404
[28] RSC Advances, 2014, vol. 4, # 99, p. 55827 - 55831
[29] Letters in Drug Design and Discovery, 2015, vol. 12, # 4, p. 314 - 318
[30] RSC Advances, 2014, vol. 4, # 27, p. 14248 - 14253
[31] Chemical and Pharmaceutical Bulletin, 2014, vol. 62, # 6, p. 524 - 527
[32] Oriental Journal of Chemistry, 2015, vol. 31, # 4, p. 1873 - 1885
[33] Pharmazie, 2018, vol. 73, # 3, p. 123 - 127
[34] Bioorganic Chemistry, 2018, vol. 81, p. 88 - 92
[35] Molecules, 2018, vol. 23, # 10,
  • 5
  • [ 100-09-4 ]
  • [ 2746-25-0 ]
Reference: [1] Asian Journal of Chemistry, 2014, vol. 26, # 7, p. 2092 - 2098
  • 6
  • [ 100-09-4 ]
  • [ 3290-99-1 ]
YieldReaction ConditionsOperation in experiment
87% at 250℃; Microwave irradiation General procedure: Acyl hydrazides were synthesized in excellent yields from thereaction of substituted aryl acids (0.010 mol) with hydrazine hydrate(0.012 mol) in absence of organic solvents under microwaveirradiation (300 W, 250 C) for 4e8 min. Spectral analysis of thesynthesized hydrazides are consistent with the proposed structuresand with those reported [58].
Reference: [1] Journal of Chemical Research - Part S, 2003, # 12, p. 768 - 769
[2] European Journal of Medicinal Chemistry, 2017, vol. 138, p. 396 - 406
[3] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2010, vol. 49, # 4, p. 526 - 531
[4] European Journal of Medicinal Chemistry, 2014, vol. 77, p. 231 - 242
[5] Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences, 2011, vol. 66, # 12, p. 1202 - 1208
[6] Heterocyclic Communications, 2002, vol. 8, # 6, p. 601 - 606
[7] Journal of Heterocyclic Chemistry, 2010, vol. 47, # 4, p. 838 - 845
[8] Journal of Chemical Research, 2010, vol. 34, # 12, p. 680 - 683
[9] Journal of Chemical Research, 2011, vol. 35, # 4, p. 234 - 237
[10] Journal of Chemical Research, 2011, vol. 35, # 6, p. 364 - 367
[11] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 21, p. 6293 - 6301
[12] Journal of Molecular Structure, 2011, vol. 1003, # 1-3, p. 52 - 61
[13] Journal of Molecular Structure, 2012, vol. 1011, p. 121 - 127
[14] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 24, p. 7246 - 7250
[15] Arzneimittel-Forschung/Drug Research, 2011, vol. 61, # 8, p. 452 - 457
[16] Letters in Drug Design and Discovery, 2012, vol. 9, # 3, p. 276 - 281
[17] Angewandte Chemie - International Edition, 2012, vol. 51, # 19, p. 4666 - 4670
[18] Molecules, 2012, vol. 17, # 5, p. 5095 - 5107
[19] Journal of Chemical Research, 2012, vol. 36, # 7, p. 383 - 386
[20] Journal of the Indian Chemical Society, 2012, vol. 89, # 2, p. 281 - 285
[21] Chemical Communications (Cambridge, United Kingdom), 2012, vol. 48, # 92, p. 11307 - 11309,3
[22] Journal of Agricultural and Food Chemistry, 2012, vol. 60, # 47, p. 11649 - 11656
[23] European Journal of Medicinal Chemistry, 2013, vol. 61, p. 26 - 40
[24] Journal of the Brazilian Chemical Society, 2013, vol. 24, # 1, p. 115 - 120
[25] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 8, p. 2286 - 2297
[26] Journal of the Chilean Chemical Society, 2012, vol. 57, # 4, p. 1492 - 1496
[27] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 13, p. 3839 - 3849
[28] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 17, p. 5395 - 5406
[29] Bulletin of the Korean Chemical Society, 2012, vol. 33, # 12, p. 3943 - 3949
[30] Bulletin of the Korean Chemical Society, 2012, vol. 33, # 12, p. 4180 - 4184
[31] Medicinal Chemistry Research, 2013, vol. 22, # 10, p. 4980 - 4991
[32] European Journal of Medicinal Chemistry, 2013, vol. 65, p. 276 - 283
[33] European Journal of Medicinal Chemistry, 2014, vol. 71, p. 185 - 198
[34] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2013, vol. 115, p. 683 - 689
[35] Chemical Biology and Drug Design, 2013, vol. 82, # 5, p. 546 - 556
[36] European Journal of Medicinal Chemistry, 2014, vol. 74, p. 73 - 84
[37] Tetrahedron, 2014, vol. 70, # 12, p. 2190 - 2194
[38] Journal of the Brazilian Chemical Society, 2014, vol. 25, # 1, p. 104 - 111
[39] Medicinal Chemistry Research, 2014, vol. 23, # 4, p. 2080 - 2092
[40] Dalton Transactions, 2014, vol. 43, # 20, p. 7554 - 7560
[41] Medicinal Chemistry Research, 2014, vol. 23, # 4, p. 1661 - 1671
[42] Molecules, 2014, vol. 19, # 3, p. 3436 - 3439
[43] Archives of Pharmacal Research, 2014, vol. 37, # 7, p. 852 - 861
[44] Synthetic Communications, 2014, vol. 44, # 18, p. 2724 - 2737
[45] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 17, p. 4629 - 4636
[46] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 17, p. 4629 - 4636
[47] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 22, p. 5154 - 5156
[48] RSC Advances, 2015, vol. 5, # 17, p. 12807 - 12820
[49] Phosphorus, Sulfur and Silicon and the Related Elements, 2015, vol. 190, # 7, p. 1045 - 1055
[50] Chemical Communications, 2015, vol. 51, # 76, p. 14365 - 14368
[51] Letters in Organic Chemistry, 2015, vol. 12, # 9, p. 637 - 644
[52] Medicinal Chemistry Research, 2015, vol. 24, # 12, p. 4166 - 4180
[53] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 17, p. 6014 - 6024
[54] Comptes Rendus Chimie, 2015, vol. 18, # 12, p. 1320 - 1327
[55] RSC Advances, 2015, vol. 5, # 118, p. 97089 - 97101
[56] Asian Journal of Chemistry, 2016, vol. 28, # 3, p. 639 - 643
[57] Bioorganic Chemistry, 2016, vol. 65, p. 126 - 136
[58] Medicinal Chemistry Research, 2016, vol. 25, # 4, p. 627 - 643
[59] Molecules, 2016, vol. 21, # 5,
[60] Bioorganic Chemistry, 2016, vol. 69, p. 48 - 63
[61] Oriental Journal of Chemistry, 2016, vol. 32, # 4, p. 2155 - 2161
[62] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 21, p. 5611 - 5617
[63] Letters in Drug Design and Discovery, 2016, vol. 13, # 9, p. 968 - 981
[64] Bioorganic and Medicinal Chemistry, 2017, vol. 25, # 1, p. 213 - 220
[65] Chemical Biology and Drug Design, 2017, vol. 89, # 1, p. 47 - 60
[66] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2016, vol. 55B, # 2, p. 207 - 212
[67] Arkivoc, 2016, vol. 2017, # 2, p. 87 - 106
[68] Tetrahedron, 2017, vol. 73, # 14, p. 1867 - 1872
[69] Oriental Journal of Chemistry, 2017, vol. 33, # 1, p. 335 - 345
[70] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 2, p. 1423 - 1429
[71] Journal of Molecular Structure, 2017, vol. 1138, p. 177 - 191
[72] Patent: CN106543098, 2017, A,
[73] Synlett, 2017, vol. 28, # 11, p. 1373 - 1377
[74] European Journal of Medicinal Chemistry, 2017, vol. 138, p. 140 - 151
[75] Chemical Biology and Drug Design, 2017, vol. 90, # 2, p. 236 - 243
[76] Patent: KR101697220, 2017, B1,
[77] Bioorganic and Medicinal Chemistry, 2017, vol. 25, # 20, p. 5652 - 5661
[78] Acta Poloniae Pharmaceutica - Drug Research, 2017, vol. 74, # 5, p. 1405 - 1411
[79] Oriental Journal of Chemistry, 2017, vol. 33, # 2, p. 971 - 978
[80] Oriental Journal of Chemistry, 2017, vol. 33, # 6, p. 2930 - 2936
[81] Pharmaceutical Chemistry Journal, 2018, vol. 51, # 10, p. 907 - 917
[82] European Journal of Medicinal Chemistry, 2018, vol. 151, p. 705 - 722
[83] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1971 - 1985
[84] Molecular Crystals and Liquid Crystals, 2018, vol. 664, # 1, p. 85 - 94
[85] Journal of the Chemical Society of Pakistan, 2018, vol. 40, # 4, p. 773 - 781
[86] Chemistry and Biodiversity, 2018, vol. 15, # 9,
[87] Bioorganic Chemistry, 2019, vol. 84, p. 150 - 163
  • 7
  • [ 100-09-4 ]
  • [ 13214-64-7 ]
Reference: [1] Journal of the Chinese Chemical Society, 2016, vol. 63, # 11, p. 909 - 916
[2] Patent: CN107216282, 2017, A,
  • 8
  • [ 6148-64-7 ]
  • [ 100-09-4 ]
  • [ 2881-83-6 ]
Reference: [1] ACS Catalysis, 2017, vol. 7, # 3, p. 1554 - 1562
[2] RSC Advances, 2018, vol. 8, # 27, p. 15009 - 15020
  • 9
  • [ 1071-46-1 ]
  • [ 100-09-4 ]
  • [ 2881-83-6 ]
Reference: [1] Medicinal Chemistry, 2015, vol. 11, # 4, p. 342 - 353
  • 10
  • [ 100-09-4 ]
  • [ 2881-83-6 ]
Reference: [1] Chem. Zentralbl., 1897, vol. 68, # II, p. 616
[2] Journal of Heterocyclic Chemistry, 2016, vol. 53, # 3, p. 924 - 928
  • 11
  • [ 87932-34-1 ]
  • [ 501-94-0 ]
  • [ 100-09-4 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1983, vol. 31, # 8, p. 2712 - 2717
[2] Chemical and Pharmaceutical Bulletin, 1983, vol. 31, # 8, p. 2712 - 2717
  • 12
  • [ 5406-18-8 ]
  • [ 1929-29-9 ]
  • [ 100-09-4 ]
Reference: [1] ChemSusChem, 2016, vol. 9, # 3, p. 241 - 245
  • 13
  • [ 5406-18-8 ]
  • [ 104-01-8 ]
  • [ 1929-29-9 ]
  • [ 100-09-4 ]
Reference: [1] ChemSusChem, 2016, vol. 9, # 3, p. 241 - 245
  • 14
  • [ 100-09-4 ]
  • [ 37908-97-7 ]
Reference: [1] Journal of Chemical Research - Part S, 1999, # 1, p. 64 - 65
[2] Journal of the Chemical Society, 1927, p. 2869
  • 15
  • [ 100-09-4 ]
  • [ 37908-97-7 ]
  • [ 118-75-2 ]
Reference: [1] Zeitschrift fuer Chemie, 1866, p. 366
  • 16
  • [ 127-09-3 ]
  • [ 64-19-7 ]
  • [ 100-09-4 ]
  • [ 37908-97-7 ]
Reference: [1] Journal of the Chemical Society, 1927, p. 2869
  • 17
  • [ 99-90-1 ]
  • [ 100-09-4 ]
  • [ 7511-49-1 ]
Reference: [1] Tetrahedron Letters, 2003, vol. 44, # 52, p. 9271 - 9274
  • 18
  • [ 57544-05-5 ]
  • [ 877-22-5 ]
  • [ 91735-21-6 ]
  • [ 100-09-4 ]
Reference: [1] Heterocycles, 1987, vol. 26, # 8, p. 2117 - 2124
  • 19
  • [ 100-09-4 ]
  • [ 74317-85-4 ]
YieldReaction ConditionsOperation in experiment
91.4%
Stage #1: With bromine; sodium hydroxide In water at 0 - 5℃; for 1 h;
Stage #2: With hydrogenchloride; sodium sulfite In water; toluene at 70℃; for 1 h;
After putting 152.3 g (1.0 mol) of 4-methoxyben- zoic acid was into a 2,000 mE four-necked flask equipped with a stirrer, a thermometer, and a reflux cooling tube, 800g of water was added thereto and stirred so as to disperse 4-methoxybenzoic acid. Subsequently, 273.3 g (2.05 mol) of a 30percent sodium hydroxide aqueous solution was added. The liquid temperature was then reduced to 0° C., and 167.8 g (1.05 mol) of bromine was added dropwise at a liquid temperature of 0 to 5° C. Completion of the dropwise addition was followed by stirring for one hour at a liquid temperature of 0 to 5° C. Afier completion of the reaction, 1.28 g (0.01 mol) of sodium sulfite was added followed by addition of 100 g of toluene and raising the liquid temperature to 70° C. The organic phase was removed by a liquid separation operation, and 104.2 g (1.0 mol) of 35percent hydrochloric acid was added dropwise to the acquired aqueous phase and stirred for one hour. Precipitated crystals were collected by filtration and dried under reduced pressure to acquire 238.9 g (99.9percent purity, 91.4percent yield) of 2-bromo-4- methoxybenzoic acid.
Reference: [1] Patent: US2018/86687, 2018, A1, . Location in patent: Paragraph 0064
  • 20
  • [ 100-09-4 ]
  • [ 99-58-1 ]
  • [ 74317-85-4 ]
Reference: [1] Journal of Organic Chemistry, 2007, vol. 72, # 9, p. 3419 - 3429
  • 21
  • [ 77184-81-7 ]
  • [ 5722-93-0 ]
  • [ 77184-89-5 ]
  • [ 100-09-4 ]
Reference: [1] Bulletin of the Chemical Society of Japan, 1980, vol. 53, # 9, p. 2630 - 2633
  • 22
  • [ 100-09-4 ]
  • [ 54435-09-5 ]
Reference: [1] Journal of Organic Chemistry, 2007, vol. 72, # 9, p. 3419 - 3429
[2] Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical, 1983, vol. 22, # 9, p. 770 - 773
  • 23
  • [ 100-09-4 ]
  • [ 23676-09-7 ]
Reference: [1] Justus Liebigs Annalen der Chemie, 1867, vol. 141, p. 258
  • 24
  • [ 100-09-4 ]
  • [ 37934-89-7 ]
Reference: [1] Angewandte Chemie - International Edition, 2013, vol. 52, # 28, p. 7317 - 7320[2] Angew. Chem., 2013, vol. 125, # 28, p. 7458 - 7461,4
  • 25
  • [ 100-09-4 ]
  • [ 21971-21-1 ]
Reference: [1] Journal of Organic Chemistry, 2007, vol. 72, # 9, p. 3419 - 3429
  • 26
  • [ 20714-90-3 ]
  • [ 20714-89-0 ]
  • [ 100-09-4 ]
Reference: [1] Journal of Organic Chemistry, 2003, vol. 68, # 19, p. 7234 - 7242
  • 27
  • [ 616-45-5 ]
  • [ 100-09-4 ]
  • [ 72432-10-1 ]
YieldReaction ConditionsOperation in experiment
91% With silica gel In tolueneReflux Into a 250 mL four-necked flask, 150 mL of toluene, p-methoxybenzoic acid (34 g, 0.2 mol), α-pyrrolidone (17 g, 0.2 mol), silica (6 g, 10 mmol) were refluxed, and methanol was distilled off. . Methanol was evaporated and cooled to 15°C to precipitate a solid. Filter to obtain a solid cake. Dissolve with 95percent ethanol, decolorize the activated carbon, filter it while hot, crystallization after cold, filter and filter cake to obtain dried aniracetam finished product 39.5g. (Yield is 91percent)
79% With zirconyl chloride octahydrate In chlorobenzene at 131℃; for 18 h; Dean-Stark General procedure: In a typical reaction, a round-bottom flask equipped with a Dean-Stark apparatus, a magnetic stirring bar and temperature controller was charged with 2-pyrrolidone (5.8 mmol), palmitic acid (5.8 mmol), ZrOCl2.8H2O (0.58 mmol) and mesitylene (20 ml). When methyl palmitate was used as acylating agent, the Dean-Stark bridge was filled with 4Å molecular sieves to remove methanol from the reaction mixture. The set-up was flushed with gaseous nitrogen for 10 min before the onset of the reaction. The reaction vessel was then heated and kept for 18 h under reflux conditions.
Reference: [1] Patent: CN107840816, 2018, A, . Location in patent: Paragraph 0036-0049
[2] Tetrahedron Letters, 2018, vol. 59, # 17, p. 1646 - 1650
[3] Patent: EP2604592, 2014, B1, . Location in patent: Paragraph 0018
  • 28
  • [ 100-09-4 ]
  • [ 133865-89-1 ]
Reference: [1] Patent: CN107915657, 2018, A,
  • 29
  • [ 100-09-4 ]
  • [ 133238-87-6 ]
  • [ 141627-42-1 ]
YieldReaction ConditionsOperation in experiment
72.7%
Stage #1: With Methyltrichlorosilane In chlorobenzene at 20 - 40℃; for 4 h;
Stage #2: With ethanol In chlorobenzene at 0℃;
EXAMPLE 133.94 g of chlorobenzene (35 mmol, 7 eq.), 1.05 g of iron chloride (6.5 mmol, 1.3 eq.) and 0.80 g of para-anisic acid (5.25 mmol, 1.05 eq.) are introduced into a 30 ml Schott tube with magnetic stirring at 500 rpm and at ambient temperature.1.09 g of 2-n-butyl-5-nitrobenzofuran (5 mmol, 1 eq.) and 1.12 g of trichloromethylsilane (7.5 mmol, 1.5 eq.) are then added dropwise, and then the reaction mixture is put, with stirring, at a temperature of 40° C. for 4 hours.The reaction mixture is then cooled to 0° C. by means of an ice-bath, and 3 ml of ethanol are added.The mixture is diluted with 25 ml of chlorobenzene and filtered over sintered glass of no. 2 porosity.The filtrate (organic phase) is then washed three times with 25 ml of a 1 N hydrochloric acid solution.The organic phase is dried over magnesium sulfate and then concentrated under reduced pressure.The product is isolated from the crude reaction mixture by separation on a column of silica (silica gel 60 of diameter 0.2 to 0.5 mm), the eluant being a heptane/ethyl acetate mixture going from a ratio of 95:5 to 80:20 during the elution.1.28 g of 2-n-butyl-5-nitro-8-(4'-methoxy)acetophenonebenzofuran (3.64 mmol, which corresponds to a yield of 72.7percent) in the form of a white solid (m.p.=94.7° C.) are then obtained.The NMR characteristics of the resulting product are as follows:1H NMR (200 MHz, CDCl3): δ (ppm)=0.87-0.92 (t, 3H, J=7.2 Hz); 1.30-1.42 (m, 2H); 1.72-1.82 (m, 2H); 2.90-2.95 (t, 2H, J=7.9 Hz); 3.13 (s, 3H); 6.98-7.01 (d, 2H, J=9.3 Hz); 7.55-7.58 (d, 1H, J=9.6 Hz); 7.82-7.85 (d, 2H, J=9 Hz); 8.20-8.24 (dd, 1H, J2=9.2 Hz, J2=2.4 Hz); 8.33-8.34 (d, 1H, J=2.7 Hz).
Reference: [1] Patent: US2008/154049, 2008, A1, . Location in patent: Page/Page column 9
Same Skeleton Products
Historical Records

Similar Product of
[ 100-09-4 ]

Chemical Structure| 69838-89-7

A1269591[ 69838-89-7 ]

4-Methoxy-[7-13C]-benzoic Acid

Reason: Stable Isotope

Related Functional Groups of
[ 100-09-4 ]

Aryls

Chemical Structure| 586-38-9

[ 586-38-9 ]

3-Methoxybenzoic acid

Similarity: 0.98

Chemical Structure| 46331-50-4

[ 46331-50-4 ]

5-Methoxyisophthalic acid

Similarity: 0.98

Chemical Structure| 62089-34-3

[ 62089-34-3 ]

3-Methoxy-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 121-98-2

[ 121-98-2 ]

Methyl 4-methoxybenzoate

Similarity: 0.95

Chemical Structure| 55289-06-0

[ 55289-06-0 ]

3-Methoxy-2-methylbenzoic acid

Similarity: 0.95

Ethers

Chemical Structure| 586-38-9

[ 586-38-9 ]

3-Methoxybenzoic acid

Similarity: 0.98

Chemical Structure| 46331-50-4

[ 46331-50-4 ]

5-Methoxyisophthalic acid

Similarity: 0.98

Chemical Structure| 62089-34-3

[ 62089-34-3 ]

3-Methoxy-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 121-98-2

[ 121-98-2 ]

Methyl 4-methoxybenzoate

Similarity: 0.95

Chemical Structure| 55289-06-0

[ 55289-06-0 ]

3-Methoxy-2-methylbenzoic acid

Similarity: 0.95

Carboxylic Acids

Chemical Structure| 586-38-9

[ 586-38-9 ]

3-Methoxybenzoic acid

Similarity: 0.98

Chemical Structure| 46331-50-4

[ 46331-50-4 ]

5-Methoxyisophthalic acid

Similarity: 0.98

Chemical Structure| 62089-34-3

[ 62089-34-3 ]

3-Methoxy-5-methylbenzoic acid

Similarity: 0.98

Chemical Structure| 55289-06-0

[ 55289-06-0 ]

3-Methoxy-2-methylbenzoic acid

Similarity: 0.95

Chemical Structure| 6880-04-2

[ 6880-04-2 ]

4-Methoxy-3-methylbenzoic acid

Similarity: 0.95